Janssen-Cilag Australia has
welcomed the TGA approval of
Invokana (canagliflozin), an oral
once-daily sodium glucose cotransporter
2 (SGLT2) inhibitor, for
type 2 diabetes mellitus.
The new product is approved
for both monotherapy in lieu of
metformin, and as combination
therapy with other agents including
insulin, when these plus diet and
exercise don’t provide adequate
glycaemic control.The above article was sent to subscribers in Pharmacy Daily's issue from 24 Oct 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Oct 13
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.